Keros Therapeutics, Inc. (KROS)
11.08
+0.05
(+0.45%)
USD |
NASDAQ |
Aug 31, 16:00
11.07
-0.01
(-0.09%)
Pre-Market: 20:00
Keros Therapeutics Cash from Operations (Annual) : 107.50M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 107.50M |
| December 31, 2024 | -160.87M |
| December 31, 2023 | -124.51M |
| December 31, 2022 | -70.06M |
| Date | Value |
|---|---|
| December 31, 2021 | -62.15M |
| December 31, 2020 | -36.89M |
| December 31, 2019 | -16.00M |
| December 31, 2018 | 7.042M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Incyte Corp. | 1.413B |
| Nurix Therapeutics, Inc. | -249.46M |
| ACADIA Pharmaceuticals, Inc. | 109.84M |
| Alnylam Pharmaceuticals, Inc. | 524.08M |
| Anika Therapeutics, Inc. | 11.19M |